| Features: |
|
Protocatechuic acid (PCA; 3,4-dihydroxybenzoic acid) is a
naturally occurring phenolic acid found in many fruits, vegetables, grains,
medicinal plants and plant-derived foods. PCA also occurs as a metabolite of
several dietary polyphenols and anthocyanins. It has demonstrated antioxidant,
anti-inflammatory, neuroprotective, cardioprotective and anticancer activities
in preclinical studies. In Alzheimer-related models, PCA has improved learning
and memory, reduced amyloid-β deposition and neuroinflammation, attenuated
oxidative stress and supported cholinergic and neurotrophic signalling. In
APP/PS1 transgenic mice, PCA reduced amyloid deposition and inflammatory
responses while improving cognitive deficits. More recent AD-model studies
also report improvement of cognitive function through modulation of cholinergic
synaptic signalling. In cancer models, PCA can suppress proliferation,
migration and inflammatory signalling and promote apoptosis through mechanisms
involving ROS regulation, NF-κB, PI3K/AKT, MAPK and mitochondrial apoptotic
pathways. PCA is listed as a separate product because purified
protocatechuic acid has been directly administered and studied independently
of the botanical extracts from which it originates. (Example EGb 761) Current therapeutic evidence
remains predominantly preclinical. High PCA Sources Black/purple rice bran - High Hibiscus / roselle - High Açaí - High Black rice - High Purple rice - High Black wild rice - Moderate Blood orange - High precursor source Blackcurrant - Moderate-high Blackberry - Moderate-high Aronia / chokeberry - Moderate-high Dark cherries - Moderate Onion - Moderate Potato - Moderate Barley tea - Moderate |
| Source: |
| Type: |
| GSK3β is a crucial member of the Wnt/β-catenin-, hedgehog (Hh)-, notch- and c-myc-mediated major pro-oncogenic pathways, while also being a negative regulator of epithelial–mesenchymal transition (EMT). Accumulating evidence defines GSK3β as a potential therapeutic target in cancer, thus encouraging the development of GSK3β inhibitors for cancer treatment. Glycogen synthase kinase 3 beta (GSK-3β) is a serine/threonine kinase that plays a crucial role in various cellular processes, including cell proliferation, differentiation, and apoptosis. Its expression and activity have been implicated in several types of cancer, often with varying prognostic implications. In many cancers, decreased GSK-3β activity is associated with poor prognosis, while in others, increased activity may correlate with aggressive disease. |
| 7200- | EGb 761, | PCA, | Optimized Ginkgo biloba extract EGb 761®: boosted therapeutic benefits with minimized CYP enzyme interference |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:435 Target#:385 State#:% Dir#:4
wNotes=0 sortOrder:rid,rpid